Industry Update View All
Optimizing the Therapeutic Landscape in Managing Dyslipidemia – A Discussion on the 2025 Update of the 2019 ESC/EAS Guidelines

Since the publication of the 2019 European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Guidelines for the management of dyslipidemia, various landmark clinical trials regarding therapies for dyslipidemia have been publ...

Dr. Roy LauFeb 11, 2026
Uncovering the Role of Zanubrutinib in Countering Follicular Lymphoma

Follicular lymphoma (FL) is an indolent form of non-Hodgkin’s lymphoma (NHL) that originates from germinal centre B cells 1 and is the second most common NHL subtype worldwide. Although first-line treatment achieves a complete response (CR) an...

Dr. Roy LauFeb 11, 2026
Cure Hodgkin’s Lymphoma and Thrive Fearlessly in the Future Chapters

Hodgkin’s lymphoma (HL) is a rare monoclonal lymphoid neoplasm that consists of two subtypes: classical HL (cHL- 95% cases) and nodular lymphocyte predominant HL (NLP-HL) 1,2 . Notably, cHL has a bimodal age distribution that initially peaks a...

Dr. Mohsin RoshanFeb 11, 2026
FeaturedView All